drugset / Trial / NCT04397523

Efficacy and Safety of COVID-19 Convalescent Plasma

NCT04397523 ↗

NaSingle-groupOpen-labelTreatment

Summary

Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection

Timeline

Start
2020-04-30
Primary completion
2021-05-10
Completion
2021-05-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-SARS-CoV-2 convalescent plasma Protein / enzyme biologic — —

Indications